@article{744b1d47b0164c8193cd995349896ecc,
title = "Strengthening the reporting of genetic risk prediction studies (GRIPS): Explanation and elaboration",
abstract = "The rapid and continuing progress in gene discovery for complex diseases is fuelling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but they vary widely in completeness of reporting and apparent quality. Transparent reporting of the strengths and weaknesses of these studies is important to facilitate the accumulation of evidence on genetic risk prediction. A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS), building on the principles established by prior reporting guidelines. These recommendations aim to enhance the transparency, quality and completeness of study reporting, and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct or analysis.",
keywords = "Genetic, Guidelines, Methodology, Reporting, Risk prediction",
author = "Janssens, {A. Cecile J.W.} and Ioannidis, {John P.A.} and Sara Bedrosian and Paolo Boffetta and Dolan, {Siobhan M.} and Nicole Dowling and Isabel Fortier and Freedman, {Andrew N.} and Grimshaw, {Jeremy M.} and Jeffrey Gulcher and Marta Gwinn and Hlatky, {Mark A.} and Holly Janes and Peter Kraft and Stephanie Melillo and O'Donnell, {Christopher J.} and Pencina, {Michael J.} and David Ransohoff and Schully, {Sheri D.} and Daniela Seminara and Winn, {Deborah M.} and Wright, {Caroline F.} and {Van Duijn}, {Cornelia M.} and Julian Little and Khoury, {Muin J.}",
note = "Funding Information: Examples. “This study was supported by grants from the National Heart, Lung, and Blood Institute and National Cancer Institute, National Institutes of Health; the Donald W. Reynolds Foundation; and the Leducq Foundation. Additional support for DNA extraction, reagents, and data analysis was provided by Roche Diagnostics and Amgen. Genotyping of the 9p21.3 variant was performed by Celera. The funding sources had no role in the design, conduct, or reporting of this study or the decision to submit the manuscript for publication.” [53] ",
year = "2011",
month = apr,
doi = "10.1007/s10654-011-9551-z",
language = "English (US)",
volume = "26",
pages = "313--337",
journal = "European Journal of Epidemiology",
issn = "0393-2990",
publisher = "Springer Netherlands",
number = "4",
}